Clinical exome or genome sequencing may deliberately examine selected genes for medically actionable findings unrelated to the reason for testing. These secondary findings are different from the primary diagnostic search. The distinction should be explained before testing, because a result can create new follow-up needs even when the original diagnostic question remains unanswered.
Explain the choice clearly
The ACMG’s 2021 secondary-findings policy supports an informed opportunity to opt out. A useful conversation describes the kinds of health risks that may be identified, the possibility of implications for relatives, and the limits of what a negative result means. The local laboratory’s actual consent process and reporting policy should be clear rather than assumed. Read the ACMG policy update.
People may value information differently. Some welcome potentially preventive knowledge; others may wish to limit unexpected information at that time. Documenting the decision helps the clinical team distinguish an analysis that was not performed from an analysis that found no reportable result.
Check the version and variant rules
The ACMG SF v3.3 publication from 2025 illustrates that the recommended list is versioned and that reporting can depend on gene-specific variant and inheritance criteria. It is not a list of every gene that influences health. A gene’s inclusion does not mean that every rare change in it should be returned as actionable. Read the version 3.3 list.
When reviewing a report, note which list and laboratory policy were used. A later change to a list does not establish that an earlier laboratory has automatically reanalyzed stored data. If reassessment is relevant, clarify the service’s process rather than implying continuous surveillance.
Plan beyond disclosure
- Identify who will explain a positive result and arrange appropriate specialist assessment.
- Distinguish genetic susceptibility from an existing clinical diagnosis.
- Discuss family implications in a way that respects confidentiality and individual choice.
- Explain that a negative secondary-findings result does not replace routine care or evaluation of concerning symptoms.
Clinical action depends on the confirmed finding, the individual’s circumstances and condition-specific guidance. Avoid presenting the analysis as a comprehensive health screen or a guarantee of prevention. The quality of a secondary-findings program depends on informed choice and an accessible follow-up pathway as much as on the sequencing itself.